Substituted Furanyl Compounds Targeting Hedgehog and eIF4E Pathways
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer therapies lack effective and safe alternatives that can inhibit tumor growth with minimal toxicity to normal cells and minimal on-target side effects, particularly for triple negative breast cancer and other aggressive cancer types.
Innovation Solution
Development of substituted furanyl compounds that target the Hedgehog pathway and eIF4E, disrupting cap-dependent protein translation initiation to inhibit cancer cell proliferation and angiogenesis.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional cancer therapies are used to inhibit tumor growth, then cancer cell proliferation is suppressed, but toxicity to normal cells and on-target side effects increase
Solution Approach 1:
The patent applies local quality by designing compounds with specific molecular features (furanyl ring, sulfonamide group, heteroaryl substituents) that confer selective affinity for cancer cell targets versus normal cells. The compounds target specific pathways (Hedgehog signaling, eIF4E-mediated translation) that are dysregulated in cancer but less critical in normal physiology, achieving localized therapeutic effect on tumor cells while sparing normal tissue.
Solution Approach 2:
The patent employs parameter changes by optimizing multiple molecular parameters simultaneously: the core furanyl structure, the sulfonamide linkage, the heteroaryl substituent type (pyridyl, pyrimidinyl, triazolyl), and their spatial arrangements. These structural parameter variations enable fine-tuning of target binding affinity, cellular uptake, and metabolic stability to maximize anticancer efficacy while minimizing off-target toxicity.
2Productivity
If aggressive cancer therapies are used to treat triple negative breast cancer, then tumor progression is controlled, but side effects and lack of targeted specificity worsen
Solution Approach 1:
The patent uses intermediary molecules (the furanyl sulfonamide compounds) that mediate between the therapeutic goal of inhibiting triple negative breast cancer and the constraint of minimizing side effects. These compounds act as selective intermediaries by targeting specific molecular pathways (Hedgehog signaling, cap-dependent translation via eIF4E) that are aberrantly activated in triple negative breast cancer, providing targeted intervention without the broad toxicity of conventional chemotherapy.
Solution Approach 2:
The patent applies segmentation by dividing the complex problem of treating triple negative breast cancer into targeted molecular pathways. Instead of using non-specific cytotoxic agents, the invention segments the therapeutic approach to target specific dysregulated pathways (Hedgehog signaling pathway components, eIF4E-mediated translation initiation) that drive triple negative breast cancer progression, thereby achieving specificity and reducing off-target side effects.
3Adaptability or versatility
If targeted therapy is developed for specific cancer pathways, then therapeutic specificity improves, but treatment complexity and development difficulty increase
Solution Approach 1:
The patent applies universality by designing a core furanyl sulfonamide scaffold that can accommodate multiple heteroaryl substituents (pyridyl, pyrimidinyl, triazolyl, oxazolyl) with different target profiles. This universal scaffold enables a single chemical platform to target multiple cancer pathways (Hedgehog signaling, eIF4E-mediated translation) and potentially different cancer types, reducing overall treatment complexity while maintaining high therapeutic specificity through substituent optimization.
Data Source
Figure 1
AI summary
Provided herein are substituted furanyl compounds of formula (I), pharmaceutical compositions comprising the compounds, methods of their preparation, and methods of their use. The compounds provided herein are useful for the treatment, prevention, and/or amelioration of various disorders, including cancer and proliferative disorders. In one embodiment, the compounds provided herein modulate eIF4E activity. In one embodiment, the compounds provided herein modulate the Hedgehog pathway activity. In one embodiment, the compounds provided herein are used in combination with surgery, radiation therapy, immuno therapy and/or one or more additional anticancer drugs for the treatment, prevention, and/or amelioration of cancer and proliferative disorders.